Kyverna Therapeutics (NASDAQ:KYTX) held its 2026 annual meeting of stockholders, with shareholders electing two directors and approving the company’s independent auditor, according to the meeting transcript.
Warner Biddle, Kyverna’s chief executive officer and chairman of the meeting, opened the session by describing 2026 as “a pivotal inflection year” for the company as it works to transition into a commercial-stage business. Biddle said the company is supported by “strong clinical execution and significant regulatory progress,” pointing to data in stiff person syndrome and generalized myasthenia gravis for its investigational therapy mivocabtagene.
“As we execute on our rolling BLA submission and prepare for the potential commercial launch of the first approved CAR T-cell therapy in autoimmune diseases, we are excited to lay the foundation for a multi-indication neuroimmunology franchise that reinforces our leadership position in this space,” Biddle said.
Stockholders Elect Two Directors
The company said approximately 73% of its issued and outstanding common shares were represented at the meeting, which was sufficient to establish a quorum. The record date for the meeting was March 30, 2026, and notice of the availability of proxy materials was mailed April 13, 2026, according to the meeting proceedings.
The first proposal before shareholders was the election of two Class II directors. Biddle said the board had nominated and recommended votes for Ian Clark and Christi Shaw, both current directors of Kyverna. No stockholder nominations were received under the company’s advance notice bylaws, and Biddle declared nominations closed.
Greg Martini, Kyverna’s chief financial officer and secretary of the meeting, reported preliminary results showing that Clark and Shaw were each elected as Class II directors. Each will serve until the company’s 2029 annual meeting of stockholders, or until a successor is duly elected and qualified.
BDO Ratified as Independent Auditor
The second proposal was the ratification of BDO USA as Kyverna’s independent registered public accounting firm and independent auditor for the year ending Dec. 31, 2026. Biddle introduced Bo Monaco, a partner at BDO USA, noting that Monaco was available to answer appropriate questions concerning the independent audit.
Martini reported that shareholders approved the ratification of BDO’s appointment, based on preliminary voting results provided by the inspector of election. John Holowach of Broadridge Financial Solutions served as inspector of election for the meeting.
The company said the inspector of election would provide a written report of the final vote count, and that a final tally would be published in a current report on Form 8-K filed with the Securities and Exchange Commission on or before June 2, 2026.
No Stockholder Questions Submitted
After the voting results were announced, Biddle said there was no further business to come before the meeting and noted that the company had not received any questions regarding the agenda items. The annual meeting was then adjourned.
Biddle closed by thanking stockholders for attending and for their continued support of Kyverna Therapeutics.
About Kyverna Therapeutics (NASDAQ:KYTX)
Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.
The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.
